These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30667364)

  • 1. Targeting autophagy in thyroid cancers.
    Wei W; Hardin H; Luo QY
    Endocr Relat Cancer; 2019 Apr; 26(4):R181-R194. PubMed ID: 30667364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Therapy in Thyroid Cancer: State of the Art.
    Valerio L; Pieruzzi L; Giani C; Agate L; Bottici V; Lorusso L; Cappagli V; Puleo L; Matrone A; Viola D; Romei C; Ciampi R; Molinaro E; Elisei R
    Clin Oncol (R Coll Radiol); 2017 May; 29(5):316-324. PubMed ID: 28318881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy in radioiodine refractory thyroid cancer.
    Pacini F; Brilli L; Marchisotta S
    Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):520-5. PubMed ID: 19910905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine.
    Bulotta S; Celano M; Costante G; Russo D
    Endocrine; 2016 May; 52(2):214-21. PubMed ID: 26690657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Target therapies for radioiodine refractory advanced thyroid tumors.
    Schlumberger M
    J Endocrinol Invest; 2012; 35(6 Suppl):40-4. PubMed ID: 23014073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on thyroid cancer treatment.
    Regalbuto C; Frasca F; Pellegriti G; Malandrino P; Marturano I; Di Carlo I; Pezzino V
    Future Oncol; 2012 Oct; 8(10):1331-48. PubMed ID: 23130931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Significance of BRAFV600E Mutation in Thyroid Cancer in Terms of Novel Targeted Therapies - Overview of Current Knowledge and Studies.
    Iva J; Filip G; Martin B; Pavel Ž; Jan Č
    Klin Onkol; 2018; 31(5):339-344. PubMed ID: 30541319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets.
    Spitzweg C; Bible KC; Hofbauer LC; Morris JC
    Lancet Diabetes Endocrinol; 2014 Oct; 2(10):830-42. PubMed ID: 24898835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Advanced Thyroid Cancer.
    Vaccher E; Schioppa O; Martellotta F; Fornasier G; Giacomin E; Re FL; Baldo P; Corona G; Gobitti C
    Recent Pat Anticancer Drug Discov; 2019; 14(3):226-241. PubMed ID: 31362663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice.
    Tirrò E; Martorana F; Romano C; Vitale SR; Motta G; Di Gregorio S; Massimino M; Pennisi MS; Stella S; Puma A; Gianì F; Russo M; Manzella L; Vigneri P
    Genes (Basel); 2019 Sep; 10(9):. PubMed ID: 31540307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted treatments of radio-iodine refractory differentiated thyroid cancer.
    de la Fouchardière C
    Ann Endocrinol (Paris); 2015 Feb; 76(1 Suppl 1):1S34-9. PubMed ID: 26826481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis.
    Shen CT; Qiu ZL; Luo QY
    Endocr Relat Cancer; 2014 Apr; 21(2):253-61. PubMed ID: 24302666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms of resistance to kinase inhibitors and redifferentiation in thyroid cancers.
    Hofmann MC; Kunnimalaiyaan M; Wang JR; Busaidy NL; Sherman SI; Lai SY; Zafereo M; Cabanillas ME
    Endocr Relat Cancer; 2022 Nov; 29(11):R173-R190. PubMed ID: 35975971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.
    Narayanan S; Colevas AD
    Curr Treat Options Oncol; 2016 Jun; 17(6):30. PubMed ID: 27139457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The current role of targeted therapies to induce radioiodine uptake in thyroid cancer.
    Fröhlich E; Wahl R
    Cancer Treat Rev; 2014 Jun; 40(5):665-74. PubMed ID: 24485648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance.
    Hamidi S; Hofmann MC; Iyer PC; Cabanillas ME; Hu MI; Busaidy NL; Dadu R
    Front Endocrinol (Lausanne); 2023; 14():1176731. PubMed ID: 37435488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapy in refractory thyroid cancer: current achievements and limitations.
    Brilli L; Pacini F
    Future Oncol; 2011 May; 7(5):657-68. PubMed ID: 21568681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagy activity is associated with membranous sodium iodide symporter expression and clinical response to radioiodine therapy in non-medullary thyroid cancer.
    Plantinga TS; Tesselaar MH; Morreau H; Corssmit EP; Willemsen BK; Kusters B; van Engen-van Grunsven AC; Smit JW; Netea-Maier RT
    Autophagy; 2016 Jul; 12(7):1195-205. PubMed ID: 27105307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience.
    Viola D; Valerio L; Molinaro E; Agate L; Bottici V; Biagini A; Lorusso L; Cappagli V; Pieruzzi L; Giani C; Sabini E; Passannati P; Puleo L; Matrone A; Pontillo-Contillo B; Battaglia V; Mazzeo S; Vitti P; Elisei R
    Endocr Relat Cancer; 2016 Apr; 23(4):R185-205. PubMed ID: 27207700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.